BioSpace News Archive

Ascentage Pharma (6855.HK), today announced that a new preclinical study, conducted by the researchers from Fred Hutchinson Cancer Research Center, Seattle, suggests the therapeutic potential of olverembatinib (HQP1351) in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron-mediated cytokine release.

The Mark Foundation for Cancer Research announced that Ryan Schoenfeld, PhD, has been appointed Chief Executive Officer.

C2N Diagnostics, a leader in advanced brain health diagnostics that offers the PrecivityAD™ blood test as an aid to Alzheimer’s disease diagnosis, today announced its latest innovative offering for enhancing care in brain health: a high-resolution mass spectrometry-based plasma tau multi-analyte assay (p-tau MAA) for Research Use Only (RUO).

According to the United Nations, the global population aged 60 years or over was numbered 962 million in 2017 and is expected to reach nearly 2.1 billion by 2050.

Vertex Pharmaceuticals Incorporated announced that Suketu Upadhyay has been elected to its board of directors as an independent director.

The Annual General Meeting of Spago Nanomedical AB was held , May 18, 2022, at which the AGM resolved to approve the income statement and balance sheet for 2021 and discharge the Board members and the CEO from liability for the financial year 2021.

The central idea behind using single-use bioprocessing technology in the bioprocess is to decrease the cost associated with complicated steps such as cleaning, sterilization, and maintenance of steel-based bioreactor systems.

Proxima Clinical Research, a company guiding emerging medical device and pharmaceutical companies from the earliest stages of product development through commercialization, announced it has successfully received Safer Technologies Program Medical Device Designation for its client, Airway Shield™.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company.

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 9, 2022, at 10:00 a.m., at the offices of Dechert LLP, located at 32 rue de Monceau in Paris, France.